Metallicity profiles of Ultra Diffuse Galaxies in NIHAO simulations

Supernovae feedback driven expansion has proven to be a viable mechanism to explain the average properties of Ultra Diffuse Galaxies (UDGs) such as the sizes, colors, mass and internal kinematics. Here, we explore the origin of stellar metallicity gradients in feedback driven simulated UDGs from the NIHAO project and compare them with the observed distribution of metallicity gradients of both Local Group dwarfs as well as of the recently observed UDG DF44. Simulated UDGs display a large variety of metallicity profiles, showing flat to negative gradients, similarly to what is observed in LG dwarfs, while DF44 data suggest a flat to positive gradient. The variety of metallicity gradients in simulations is set by the interplay between the radius at which star formation occurs and the subsequent supernovae feedback driven stellar redistribution: rotation supported systems tend to have flat metallicity profiles while dispersion supported galaxies show negative and steep profiles. Our results suggest that UDGs are not peculiar in what regards their metallicity gradients, when compared to regular dwarfs. Desirably, a larger observational sample of UDGs' gradients shall be available in the future, in order to test our predictions.Comment: 13 pages, 6+3 figure

The Undiscovered Ultradiffuse Galaxies of the Local Group

Ultradiffuse galaxies (UDGs) are attractive candidates to probe cosmological models and test theories of galaxy formation at low masses; however, they are difficult to detect because of their low surface brightness. In the Local Group a handful of UDGs have been found to date, most of which are satellites of the Milky Way and M31, and only two are isolated galaxies. It is unclear whether so few UDGs are expected. We address this by studying the population of UDGs formed in hydrodynamic constrained simulations of the Local Group from the HESTIA suite. For a Local Group with a total enclosed mass M LG( < 2.5 Mpc) = 8 × 1012 M⊙, we predict that there are 12 ± 3 isolated UDGs (68% confidence) with stellar masses 106 ≤ M */M⊙ < 109, and effective radii R e ≥ 1.5 kpc, within 2.5 Mpc of the Local Group, of which 2 − 1 + 2 (68% confidence) are detectable in the footprint of the Sloan Digital Sky Survey (SDSS). Accounting for survey incompleteness, we find that almost the entire population of UDGs in the Local Group field would be observable in a future all-sky survey with a depth similar to the SDSS, the Dark Energy Survey, or the Legacy Survey of Space and Time. Our results suggest that there is a population of UDGs in the Local Group awaiting discovery

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events